| ID | DRAMP21375 |
|---|---|
| Sequence | GWAKLITKAIKKI |
| Length | 13 |
| Name | SP3 (De Novo Synthesis) |
| Source | synthetic construct |
| Activity | Antimicrobial, Antibacterial, Anti-Gram- |
| Pathogen | [Ref.31163671] Gram-negative bacteria:Escherichia coli ATCC 25922 (MIC=25–50 µg/mL) |
| Hemolytic Activity | [Ref.31163671] 10% hemolysis at 50–100 μg/mL against human blood cells. |
| Cytotoxicity | [Ref.31163671] The cell viability of Hepa 1-6 induced by SP3 is 80.4%, 77.0%, 87.8%, 98.0%, 76.4% and 84.5% at peptide concentrations of 3.125, 6.25, 12.5, 25, 50 and 100 μg/mL. |
| N-terminal Modification | Free |
| C-terminal Modification | Amidation |
| Linear/Cyclic/Branched | Linear |
| Uniprot | |
| PDB | |
| 3D View | |
| PDB Download | Download PDB Predicted by Alphafold2 |
| PubMed ID | 31163671 |
Physicochemical Properties
| Residues | 13 |
|---|---|
| Sequence | GWAKLITKAIKKI |
| Molecular Weight | 1469.856 |
| Grand Average of Hydropathy | 0.254 |
| Isoelectric Point | 10.478 |
| Charge at pH 7.4 | 3.547 |
| Secondary Structure | Helix: 0.385, Turn: 0.077, Sheet: 0.231 |
| Instability Index | -12.431 |
| Aromaticity | 0.077 |